Header Logo

Connection

MICHAEL TAYLOR to Adolescent

Back to Details
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Adolescent.
MICHAEL TAYLOR
Connection Strength
0.882
Adolescent
  1. Posterior fossa ependymoma: current insights. Childs Nerv Syst. 2015 Oct; 31(10):1699-706.
    View in: PubMed
    Score: 0.033
  2. [Molecular subgrouping and characterization analysis of medulloblastomas in a cohort of Japanese patients]. No Shinkei Geka. 2015 Feb; 43(2):117-25.
    View in: PubMed
    Score: 0.032
  3. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. J Neurosurg Pediatr. 2015 Mar; 15(3):236-42.
    View in: PubMed
    Score: 0.031
  4. Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol. 2013 Nov; 25(6):674-81.
    View in: PubMed
    Score: 0.029
  5. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7.
    View in: PubMed
    Score: 0.029
  6. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr; 123(4):615-26.
    View in: PubMed
    Score: 0.025
  7. Co-occurrence of congenital anomalies and childhood brain tumors in 22 million live births. Neuro Oncol. 2025 Sep 08; 27(7):1910-1922.
    View in: PubMed
    Score: 0.016
  8. The medical and functional burden of surviving childhood ependymoma: A population-based study in Ontario, Canada. Pediatr Blood Cancer. 2024 Nov; 71(11):e31275.
    View in: PubMed
    Score: 0.015
  9. Postoperative cerebellar mutism syndrome is an acquired autism-like network disturbance. Neuro Oncol. 2024 05 03; 26(5):950-964.
    View in: PubMed
    Score: 0.015
  10. The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada. J Clin Oncol. 2023 05 01; 41(13):2372-2381.
    View in: PubMed
    Score: 0.014
  11. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022 01; 28(1):125-135.
    View in: PubMed
    Score: 0.013
  12. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathol. 2021 11; 142(5):859-871.
    View in: PubMed
    Score: 0.012
  13. The transcriptional landscape of Shh medulloblastoma. Nat Commun. 2021 03 19; 12(1):1749.
    View in: PubMed
    Score: 0.012
  14. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. PLoS One. 2020; 15(12):e0243272.
    View in: PubMed
    Score: 0.012
  15. Artificial intelligence for automatic cerebral ventricle segmentation and volume calculation: a clinical tool for the evaluation of pediatric hydrocephalus. J Neurosurg Pediatr. 2021 02 01; 27(2):131-138.
    View in: PubMed
    Score: 0.012
  16. Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. Acta Neuropathol Commun. 2020 10 28; 8(1):173.
    View in: PubMed
    Score: 0.012
  17. Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. AJNR Am J Neuroradiol. 2020 09; 41(9):1718-1725.
    View in: PubMed
    Score: 0.012
  18. Radiation-induced intracranial aneurysm presenting with acute hemorrhage in a child treated for medulloblastoma. Childs Nerv Syst. 2021 04; 37(4):1387-1389.
    View in: PubMed
    Score: 0.012
  19. Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Rep Med. 2020 06 23; 1(3).
    View in: PubMed
    Score: 0.011
  20. Eye Movements and White Matter are Associated with Emotional Control in Children Treated for Brain Tumors. J Int Neuropsychol Soc. 2020 11; 26(10):978-992.
    View in: PubMed
    Score: 0.011
  21. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup. J Mol Diagn. 2020 07; 22(7):957-966.
    View in: PubMed
    Score: 0.011
  22. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 04 13; 37(4):569-583.e5.
    View in: PubMed
    Score: 0.011
  23. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. J Neuropathol Exp Neurol. 2020 04 01; 79(4):437-447.
    View in: PubMed
    Score: 0.011
  24. Molecular correlates of cerebellar mutism syndrome in medulloblastoma. Neuro Oncol. 2020 02 20; 22(2):290-297.
    View in: PubMed
    Score: 0.011
  25. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
    View in: PubMed
    Score: 0.011
  26. Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Med. 2020 01; 9(2):447-459.
    View in: PubMed
    Score: 0.011
  27. Recurrent noncoding U1?snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature. 2019 10; 574(7780):707-711.
    View in: PubMed
    Score: 0.011
  28. Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. J Neurooncol. 2019 Oct; 145(1):107-114.
    View in: PubMed
    Score: 0.011
  29. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol. 2019 08; 138(2):309-326.
    View in: PubMed
    Score: 0.011
  30. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer. 2019 06 01; 125(11):1867-1876.
    View in: PubMed
    Score: 0.010
  31. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018 12 04; 6(1):134.
    View in: PubMed
    Score: 0.010
  32. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell. 2018 09 10; 34(3):379-395.e7.
    View in: PubMed
    Score: 0.010
  33. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology. 2018 Oct; 38(5):475-483.
    View in: PubMed
    Score: 0.010
  34. Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. J Neuropathol Exp Neurol. 2018 08 01; 77(8):696-702.
    View in: PubMed
    Score: 0.010
  35. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol. 2018 08; 136(2):227-237.
    View in: PubMed
    Score: 0.010
  36. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
    View in: PubMed
    Score: 0.010
  37. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-?-OTX2-SNAIL via PTEN inhibition. Brain. 2018 05 01; 141(5):1300-1319.
    View in: PubMed
    Score: 0.010
  38. DNA methylation-based classification of central nervous system tumours. Nature. 2018 03 22; 555(7697):469-474.
    View in: PubMed
    Score: 0.010
  39. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017 Sep 01; 35(25):2934-2941.
    View in: PubMed
    Score: 0.009
  40. Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes Cancer. 2017 08; 56(8):639-650.
    View in: PubMed
    Score: 0.009
  41. Intellectual Outcome in Molecular Subgroups of Medulloblastoma. J Clin Oncol. 2016 12; 34(34):4161-4170.
    View in: PubMed
    Score: 0.009
  42. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016 07 20; 34(21):2468-77.
    View in: PubMed
    Score: 0.009
  43. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 06; 131(6):821-31.
    View in: PubMed
    Score: 0.009
  44. Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma. J Neurosurg Pediatr. 2016 Jul; 18(1):29-40.
    View in: PubMed
    Score: 0.009
  45. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729.
    View in: PubMed
    Score: 0.008
  46. Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. J Neurosurg Pediatr. 2016 Mar; 17(3):298-302.
    View in: PubMed
    Score: 0.008
  47. Executive function in paediatric medulloblastoma: The role of cerebrocerebellar connections. J Neuropsychol. 2017 06; 11(2):174-200.
    View in: PubMed
    Score: 0.008
  48. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. Pediatr Neurol. 2015 Sep; 53(3):238-242.e1.
    View in: PubMed
    Score: 0.008
  49. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015 May 11; 27(5):728-43.
    View in: PubMed
    Score: 0.008
  50. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatr Blood Cancer. 2015 Oct; 62(10):1754-60.
    View in: PubMed
    Score: 0.008
  51. Visualization and segmentation of reciprocal cerebrocerebellar pathways in the healthy and injured brain. Hum Brain Mapp. 2015 Jul; 36(7):2615-28.
    View in: PubMed
    Score: 0.008
  52. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
    View in: PubMed
    Score: 0.008
  53. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol. 2015 Mar; 129(3):449-57.
    View in: PubMed
    Score: 0.008
  54. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol. 2016 Feb; 18(2):291-7.
    View in: PubMed
    Score: 0.008
  55. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174.
    View in: PubMed
    Score: 0.008
  56. Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res. 2015 Jan 01; 21(1):184-92.
    View in: PubMed
    Score: 0.008
  57. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol. 2014 Dec; 128(6):853-62.
    View in: PubMed
    Score: 0.008
  58. New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group. Circulation. 2014 Jul 01; 130(1):79-86.
    View in: PubMed
    Score: 0.008
  59. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303.
    View in: PubMed
    Score: 0.008
  60. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014 Jul; 128(1):137-49.
    View in: PubMed
    Score: 0.007
  61. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17; 25(3):393-405.
    View in: PubMed
    Score: 0.007
  62. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer. 2014 Jul; 61(7):1190-4.
    View in: PubMed
    Score: 0.007
  63. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol. 2014 Jun 10; 32(17):1760-8.
    View in: PubMed
    Score: 0.007
  64. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20; 32(9):886-96.
    View in: PubMed
    Score: 0.007
  65. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb; 127(2):189-201.
    View in: PubMed
    Score: 0.007
  66. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29.
    View in: PubMed
    Score: 0.007
  67. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Res. 2013 Nov 15; 73(22):6734-44.
    View in: PubMed
    Score: 0.007
  68. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35.
    View in: PubMed
    Score: 0.007
  69. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst. 2013 Aug; 29(8):1253-62.
    View in: PubMed
    Score: 0.007
  70. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 2013 Mar; 125(3):359-71.
    View in: PubMed
    Score: 0.007
  71. Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro Oncol. 2012 Oct; 14(10):1294-303.
    View in: PubMed
    Score: 0.007
  72. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer. 2012 Oct 15; 131(8):1800-9.
    View in: PubMed
    Score: 0.007
  73. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol. 2012 Nov; 22(6):848-60.
    View in: PubMed
    Score: 0.007
  74. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr; 123(4):473-84.
    View in: PubMed
    Score: 0.006
  75. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):529-38.
    View in: PubMed
    Score: 0.006
  76. Association between left ventricular mass index and cardiac function in pediatric dialysis patients. Pediatr Nephrol. 2012 May; 27(5):835-41.
    View in: PubMed
    Score: 0.006
  77. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 01; 29(19):2717-23.
    View in: PubMed
    Score: 0.006
  78. Neurosurgical management of extraaxial central nervous system infections in children. J Neurosurg Pediatr. 2011 May; 7(5):441-51.
    View in: PubMed
    Score: 0.006
  79. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res. 2011 Apr 01; 17(7):1883-94.
    View in: PubMed
    Score: 0.006
  80. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010 Dec 10; 28(35):5188-96.
    View in: PubMed
    Score: 0.006
  81. Posterior fossa ependymomas: new radiological classification with surgical correlation. Childs Nerv Syst. 2010 Dec; 26(12):1765-72.
    View in: PubMed
    Score: 0.006
  82. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010 Mar 10; 28(8):1345-50.
    View in: PubMed
    Score: 0.006
  83. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20; 24(12):1924-31.
    View in: PubMed
    Score: 0.004
  84. Retrospective family study of childhood medulloblastoma. Am J Med Genet A. 2005 May 01; 134(4):399-403.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.